IRIS
TOSCANI, Denise
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.531
AS - Asia 3.116
EU - Europa 2.011
SA - Sud America 426
AF - Africa 224
Continente sconosciuto - Info sul continente non disponibili 153
OC - Oceania 1
Totale 9.462
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.405
SG - Singapore 1.009
CN - Cina 862
VN - Vietnam 504
IT - Italia 458
SE - Svezia 346
BR - Brasile 318
IE - Irlanda 311
HK - Hong Kong 215
DE - Germania 183
FI - Finlandia 170
BD - Bangladesh 160
ZA - Sudafrica 148
FR - Francia 138
TR - Turchia 114
NL - Olanda 84
CA - Canada 73
AT - Austria 67
IN - India 66
GB - Regno Unito 51
RU - Federazione Russa 48
AR - Argentina 42
MX - Messico 29
BE - Belgio 26
CZ - Repubblica Ceca 25
CI - Costa d'Avorio 23
JP - Giappone 22
IQ - Iraq 21
RO - Romania 19
ES - Italia 18
KR - Corea 18
PL - Polonia 17
CO - Colombia 14
PK - Pakistan 14
TH - Thailandia 14
UA - Ucraina 14
VE - Venezuela 14
EC - Ecuador 12
ID - Indonesia 11
PH - Filippine 11
CL - Cile 9
UZ - Uzbekistan 9
AE - Emirati Arabi Uniti 8
KE - Kenya 8
LT - Lituania 8
TN - Tunisia 8
MA - Marocco 7
PY - Paraguay 7
EG - Egitto 6
EU - Europa 6
IL - Israele 6
KZ - Kazakistan 6
TW - Taiwan 6
CR - Costa Rica 5
AL - Albania 4
BG - Bulgaria 4
BO - Bolivia 4
IR - Iran 4
JM - Giamaica 4
MY - Malesia 4
SA - Arabia Saudita 4
SN - Senegal 4
AZ - Azerbaigian 3
BW - Botswana 3
DZ - Algeria 3
ET - Etiopia 3
GT - Guatemala 3
JO - Giordania 3
KW - Kuwait 3
OM - Oman 3
PE - Perù 3
RS - Serbia 3
SC - Seychelles 3
SY - Repubblica araba siriana 3
UY - Uruguay 3
AM - Armenia 2
BY - Bielorussia 2
CH - Svizzera 2
DK - Danimarca 2
EE - Estonia 2
HN - Honduras 2
HU - Ungheria 2
MD - Moldavia 2
MU - Mauritius 2
PT - Portogallo 2
QA - Qatar 2
XK - ???statistics.table.value.countryCode.XK??? 2
AG - Antigua e Barbuda 1
BB - Barbados 1
BH - Bahrain 1
BJ - Benin 1
BN - Brunei Darussalam 1
BZ - Belize 1
CG - Congo 1
CM - Camerun 1
CY - Cipro 1
DM - Dominica 1
DO - Repubblica Dominicana 1
GD - Grenada 1
KH - Cambogia 1
Totale 9.301
Salva come PNG Salva come JPEG
Città #
Singapore 490
Ashburn 459
San Jose 373
Chandler 310
Dublin 309
Dallas 252
Santa Clara 236
Beijing 220
Hong Kong 206
Parma 163
Ho Chi Minh City 162
Johannesburg 141
Council Bluffs 128
Hanoi 118
Boardman 111
Ann Arbor 108
New York 108
Los Angeles 100
Shanghai 91
Izmir 90
Dearborn 75
Munich 71
Lauterbourg 68
Nanjing 64
Vienna 62
Princeton 57
Buffalo 45
Hefei 39
Shenyang 38
Marseille 35
Milan 32
São Paulo 31
Helsinki 29
Jacksonville 28
Toronto 28
Wilmington 27
Brussels 26
Columbus 26
Düsseldorf 25
Da Nang 24
Kunming 24
Moscow 24
Abidjan 23
Hebei 23
Bologna 21
Haiphong 20
Nanchang 20
Turku 20
Jinan 18
Tokyo 18
Montreal 17
San Mateo 17
Seattle 17
Brno 16
Jiaxing 16
Orem 16
Rome 16
The Dalles 16
Tianjin 16
Warsaw 15
Bremen 14
Chicago 14
London 14
Atlanta 13
Brooklyn 13
Norwalk 13
Frankfurt am Main 12
Houston 12
Stockholm 12
Seoul 11
Biên Hòa 10
Denver 10
Kocaeli 10
Phoenix 10
Redmond 10
Woodbridge 10
Changsha 9
Chennai 9
Focsani 9
Jakarta 9
San Francisco 9
Ankara 8
Belo Horizonte 8
Mexico City 8
Modena 8
Philadelphia 8
Poplar 8
Tashkent 8
Zhengzhou 8
Amsterdam 7
Baghdad 7
Can Tho 7
Guangzhou 7
Hải Dương 7
Ottawa 7
Pune 7
Rio de Janeiro 7
Salvador 7
Bangkok 6
Des Moines 6
Totale 5.750
Salva come PNG Salva come JPEG
Nome #
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 221
Bone marrow CX3CL1/Fractalkine is a new player of the pro-angiogenic microenvironment in multiple myeloma patients 217
(2S,4R)-4-fluoroglutamine is converted into (2S,4R)-4-fluoroglutamate by glutaminase activity and may be exploited as a PET tracer in glutamine-addicted cancers 214
[18F](2S,4R)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma 210
Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients 201
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 198
Novel targets for the treatment of relapsing multiple myeloma 194
The Proteasome and Myeloma-Associated Bone Disease 193
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets 193
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 190
Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy 187
Identification of PSMB4 and PSMD4 as novel target genes correlated with 1q21 amplification in patients with smoldering myeloma and multiple myeloma 185
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 183
Hypoxia-Inducible Factor (HIF)-1 alpha Inhibitionin Myeloma Cells Significantly Increases the Anti-Myeloma Effect of Lenalidomide in Vivo 180
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 176
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 175
ADENOSINE IN THE MYELOMA BONE MARROW NICHE: IMMUNE CHECKPOINT AND KEY PLAYER IN DISEASE PROGRESSION 171
A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors 169
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 162
Bortezomib improves bone integrity in multiple myeloma patients by blocking osteocyte death and autophagy 161
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 161
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells 158
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 155
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 154
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 153
The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells 148
Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma. 147
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 147
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 145
The impact of CD56 expression in smoldering myeloma patients on early progression 142
The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38 141
Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells 140
The osteoblastic niche in the context of multiple myeloma 139
Bone marrow stromal cell-fueled multiple myeloma growth and osteoclastogenesis are sustained by protein kinase CK2 138
Mechanistic insights into bone destruction in multiple myeloma: Cellular and molecular perspectives 135
Possible targets to treat myeloma-related osteoclastogenesis 134
Growth factor independence 1 expression in myeloma cells enhances their growth, survival, and osteoclastogenesis 134
Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis 128
The anti-myeloma effect of Lenalidomide is increased by hypoxia-inducible factor (HIF)-1a inhibition in multiple myeloma cells both in vitro and in vivo 127
High glutamate levels in the bone marrow of multiple myeloma patients promote osteoclast formation: a novel target for osteolytic bone disease 126
Gfi1 Transcription Factor Is a Pro-Survival Molecule in Multiple Myeloma Cells 126
Hypoxia-inducible factor (HIF)-1 is a therapeutic target in myeloma-induced angiogenesis and bone destruction in vitro and in vivo 126
CK2 Kinase Inhibitors Display Anti-Myeloma Effects and Antagonize Osteoclast Activity in Models of Multiple Myeloma Bone Marrow Microenvironment 124
Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma 119
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 118
Trascriptome Analysis of Bone Marrow CD14+ Monocytes Revealed Differential Expression Profiles in Symptomatic Multiple Myeloma (MM) Compared to Smoldering MM and Monoclonal Gammopathy of Undetermined Significance 117
Proteasome Inhibitors Block Myeloma-Induced Osteocyte Death in Vitro and in Vivo in Multiple Myeloma Patients 115
Relationship between bone imaging features and bone marrow cytokine and chemokine profiles in patients with monoclonal gammopathy 114
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction 110
Hypoxia-Inducible Factor (HIF)-1a Is A Therapeutic Target in Myeloma-Induced Angiogenesis and Bone Destruction in Vivo 109
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 104
NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model 104
The Metabolic Features of Osteoblasts: Implications for Multiple Myeloma (MM) Bone Disease 101
The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors 99
The role of proteasome inhibitors in multiple myeloma bone disease and bone metastasis: Effects on osteoblasts and osteocytes 99
The potential of inhibiting glutamine uptake as a therapeutic target for multiple myeloma 98
Pygo2 Is Overexpressed in Myeloma Cells With 1q21 Amplification Being Involved in Carfilzomib Resistance 97
Interleukin-3 induces activin A in bone marrow monocytes: role in multiple myeloma patients 97
Proteasome inhibitors modulate osteocyte death and autophagy in multiple myeloma 94
Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+ 93
Metabolic features of myeloma cells in the context of bone microenvironment: Implication for the pathophysiology and clinic of myeloma bone disease 92
Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules 91
Myeloma-Induced osteocyte death was blunted by proteasome inhibitors through the modulation of autophagy 90
New insights into osteogenic and chondrogenic differentiation of human bone marrow mesenchymal stem cells and their potential clinical applications for bone regeneration in pediatric orthopaedics 83
Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: Impact on myeloma-induced alterations of bone remodeling 81
Role of osteocytes in myeloma bone disease: Anti-sclerostin antibody as new therapeutic strategy 76
A metabolic trade-off between malignant plasma cells and mesenchymal stromal cells sustains multiple myeloma growth 47
FROM PRECURSOR DISEASES TO MULTIPLE MYELOMA: REMODELING OF THE OSTEOBLASTIC NICHE AT SINGLE CELL RESOLUTION 33
TARGETING GLUTAMINE METABOLISM POTENTIATES T CELL ENGAGER–MEDIATED IMMUNOTHERAPY IN MULTIPLE MYELOMA 29
PYGO2 is overexpressed in multiple myeloma patients with 1q21 amplification, driving plasma cell proliferation and cell cycle progression 19
Proteasome inhibitors blunt myeloma induced osteocyte death targeting autophagy both in vitro and in vivo in multiple myeloma patients 13
Long-term prognostic impact of chromosome 1 abnormalities in newly diagnosed multiple myeloma patients: a monocentric study 12
Totale 9.462
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.923
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.923
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022278 0 5 9 27 9 6 41 32 13 16 23 97
2022/20231.282 144 139 92 99 101 140 41 80 372 30 31 13
2023/2024556 26 37 12 14 36 185 51 22 14 35 27 97
2024/20251.663 34 75 89 154 176 171 107 75 197 128 158 299
2025/20264.084 328 307 521 379 531 217 375 178 473 384 251 140
2026/2027247 119 128 0 0 0 0 0 0 0 0 0 0
Totale 9.462